Jinhai International Group Holdings Limited (2225) AI Stock Analysis

• Market Cap: HK$11.06B
• Dividend Yield: N/A
• Average Volume (3M): 8.01M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.33
• Revenue Growth: -33.94%
• EPS Growth: -119.13%
• Country: HK
• Employees: 488
• Sector: Industrials
• Sector Strength: 72
• Industry: Staffing & Employment Services
• EPS (TTM): -0.01
• Shares Outstanding: 5,290,000,000
• 10 Day Avg. Volume: 11,309,500
• 30 Day Avg. Volume: 8,014,966
• PEG Ratio: -2.40
• Price to Book (P/B): 54.28
• Price to Sales (P/S): 34.36
• P/FCF Ratio: -404.91
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 53 Neutral
• Price Target: HK$2.00 ▲(61.29% Upside)

The score is held back primarily by weak financial performance (losses, deteriorating profitability, and negative cash flows). Technicals are supportive with an established uptrend and positive MACD, but overbought signals add risk. Valuation also weighs on the score due to ongoing losses (negative P/E) and no dividend support.

Positive Factors

Diversified business model

Multiple business lines (manufacturing, trading, logistics, property) provide durable revenue diversification and reduce reliance on a single market cycle. Over months this supports resilience to sector-specific shocks, cross-selling, and smoother cash flows versus single-segment peers.

Manageable leverage profile

A moderate debt-to-equity position suggests the company retains capacity to service obligations and access financing for operations or strategic investments. This structural flexibility lowers bankruptcy risk and preserves operational continuity over the medium term.

International distribution & partnerships

Established international distribution and supplier/distributor partnerships expand market reach and scale. Owning logistics/warehouse capabilities improves supply-chain efficiency and customer retention, supporting sustainable revenue and margin recovery potential over several months.

Negative Factors

Sharp revenue decline

A steep year-over-year revenue decline signals weakening demand or lost market share, eroding operating leverage. Sustained top-line contraction can depress margins, limit reinvestment, and impair the firm's ability to fund growth or stabilize earnings in the coming 2-6 months.

Negative operating & free cash flow

Persistent negative operating and free cash flow constrains funding for capex, debt service and working capital. Over the medium term this raises reliance on external financing or asset sales, increasing liquidity risk and potentially forcing disruptive cost or strategic changes.

Weak profitability and negative margins

Negative gross, EBIT and net margins plus negative ROE reflect structural margin pressure from costs or pricing. Continued unprofitability erodes equity and limits ability to invest in product, distribution or efficiency improvements, hampering recovery prospects over several months.

Jinhai International Group Holdings Limited Business Overview & Revenue Model

Company Description

Jinhai Medical Technology Ltd. provides manpower outsourcing and ancillary services. It offers services to the building and construction contractors also provides dormitory, warehousing, cleaning, and building maintenance services. The company was founded in 2006 and is headquartered in China.

How the Company Makes Money

Jinhai International Group Holdings Limited generates revenue through multiple streams. Its core revenue comes from the manufacturing and sale of consumer goods, particularly electronics and textiles, which are distributed both domestically and internationally. The company also earns income from its trading activities, where it acts as an intermediary between manufacturers and retailers. Additionally, Jinhai International has revenue from property investment and development, leveraging its real estate assets to generate rental income and profits from property sales. Strategic partnerships with suppliers and distributors enhance its operational efficiency and market reach, while its logistics and warehousing services further contribute to its earnings by optimizing supply chain management.

Jinhai International Group Holdings Limited Financial Statement Overview

Summary

Weak fundamentals: declining revenue growth, net losses and negative margins (EBIT/EBITDA), plus negative operating cash flow and free cash flow. Leverage appears manageable, but negative ROE and cash conversion issues keep the score low.

Income Statement

The company has experienced a decline in revenue growth, with a significant decrease in net income, resulting in negative net profit margins. The gross profit margin has also decreased, indicating pressure on profitability. Negative EBIT and EBITDA margins further highlight operational challenges.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio, indicating manageable leverage. However, the equity ratio has decreased, suggesting a reduction in equity relative to assets. Return on equity is negative due to net losses, which is a concern for investors.

Cash Flow

The cash flow statement reveals negative free cash flow and operating cash flow, indicating cash management issues. The operating cash flow to net income ratio is negative, reflecting challenges in converting earnings to cash. Free cash flow growth is also negative, pointing to potential liquidity constraints.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	38.83M	50.24M	45.64M	22.28M	21.90M	22.47M
Gross Profit	6.14M	11.48M	12.03M	10.12M	7.73M	8.85M
EBITDA	-20.18M	-16.82M	1.11M	5.25M	5.44M	2.15M
Net Income	-22.18M	-17.96M	-3.14M	468.00K	-246.21K	1.26M
Balance Sheet
Total Assets	50.15M	58.87M	62.22M	40.27M	33.77M	39.41M
Cash, Cash Equivalents and Short-Term Investments	6.97M	14.93M	26.76M	23.95M	25.91M	27.39M
Total Debt	14.67M	14.52M	10.08M	4.45M	1.87M	5.50M
Total Liabilities	22.38M	26.09M	24.73M	15.68M	9.75M	13.92M
Stockholders Equity	27.36M	31.81M	37.47M	24.37M	24.28M	25.49M
Cash Flow
Free Cash Flow	-4.86M	-4.26M	-3.15M	3.06M	2.73M	7.25M
Operating Cash Flow	-4.10M	-3.25M	-1.91M	4.24M	3.34M	7.38M
Investing Cash Flow	-1.63M	-9.22M	-6.51M	-1.15M	-2.64M	-6.04M
Financing Cash Flow	3.11M	2.93M	13.62M	-3.72M	-4.81M	-4.15M

Jinhai International Group Holdings Limited Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.24
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2225, the sentiment is Positive. The current price of 1.24 is below the 20-day moving average (MA) of 1.68, below the 50-day MA of 1.39, and below the 200-day MA of 1.27, indicating a bullish trend. The MACD of 0.20 indicates Negative momentum. The RSI at 83.80 is Negative, neither overbought nor oversold. The STOCH value of 80.53 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:2225.

Jinhai International Group Holdings Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2180	73 Outperform	HK$1.04B	6.83	11.29%	36.73%	17.49%	9.67%
6100	73 Outperform	HK$1.91B	12.42	―	―	-10.48%	30250.00%
8031	70 Outperform	HK$177.38M	―	―	―	―	―
8462	66 Neutral	HK$49.20M	4.88	7.43%	―	-11.47%	5.00%
Sector *	63 Neutral	$10.79B	15.43	7.44%	2.01%	2.89%	-14.66%
2225	53 Neutral	HK$11.06B	-82.94	-67.70%	―	-33.94%	-119.13%
6919	46 Neutral	HK$704.00M	-12.20	-4.09%	2.26%	14.29%	-200.37%

Jinhai International Group Holdings Limited Corporate Events

Jinhai Medical Technology Announces Resignation of Non-Executive Director and Vice-Chairman

Jinhai Medical Technology Limited has announced that non-executive director and vice-chairman of the board, Mr. Jiang Jiangyu, has resigned with effect from 29 January 2026 due to other business commitments requiring more of his time. The company stated that Mr. Jiang has no claims against the firm, no disagreements with the board, and no other matters needing shareholders’ attention in relation to his departure, suggesting an orderly transition. Following his resignation, the board now consists of three executive directors, one non-executive director and three independent non-executive directors, indicating that overall board composition and corporate governance remain intact despite the leadership change.

The most recent analyst rating on (HK:2225) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Jinhai International Group Holdings Limited stock, see the HK:2225 Stock Forecast page.

Jinhai Medical Technology Updates Board and Committee Structure

Jinhai Medical Technology Limited has updated its board composition effective 29 January 2026, confirming a structure that includes three executive directors led by Chairman Chen Guobao and CEO Wang Zhenfei, one non-executive director, and three independent non-executive directors. The board has also reaffirmed the membership and leadership of its audit, remuneration and nomination committees, with independent director Yan Jianjun chairing the audit and remuneration committees and Chairman Chen heading the nomination committee, underscoring the company’s emphasis on independent oversight and corporate governance in line with Hong Kong listing expectations.

The most recent analyst rating on (HK:2225) stock is a Hold with a HK$2.00 price target. To see the full list of analyst forecasts on Jinhai International Group Holdings Limited stock, see the HK:2225 Stock Forecast page.

Jinhai Medical Technology Relocates Hong Kong Office

Jinhai Medical Technology Limited has announced a change in its principal place of business in Hong Kong, effective from November 19, 2025. The relocation to Chinachem Century Tower in Wanchai signifies a strategic move that could enhance its operational efficiency and market positioning within the region.

The most recent analyst rating on (HK:2225) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Jinhai International Group Holdings Limited stock, see the HK:2225 Stock Forecast page.

Jinhai Medical Technology Partners with Medtronic Changzhou for Spinal Endoscopy Advancement

Jinhai Medical Technology Limited announced a strategic cooperation framework agreement with Medtronic Changzhou to promote real-time navigation and tracking spinal endoscope techniques in the PRC. This collaboration aims to develop advanced integrated solutions for spinal endoscopy, facilitate academic exchanges, and support clinical demonstrations and training. The agreement, initially set for one year, can be renewed, and formal agreements will be established as conditions mature, potentially enhancing Jinhai’s market position in the medical technology sector.

The most recent analyst rating on (HK:2225) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Jinhai International Group Holdings Limited stock, see the HK:2225 Stock Forecast page.